Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Critical Illness
NCT05558098Phase 3Completed
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in critical illness, sponsored by Hospital Israelita Albert Einstein. Started Nov 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
critical illness
Beyond the preview
Go deeper on NCT05558098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05558098.